

ANALYSIS OF EFFECTIVENESS AND SAFETY OF TRALOKINUMAB IN MODERATE-SEVERE ATOPIC DERMATITIS


Urbano-Fernández MA¹, Salmerón-Cobos AY², Cano-Domínguez S², Rodríguez-Goicoechea M³, Sierra-Torres MI², Cantudo-Cuenca R², Jiménez-Morales A²

¹ Hospital Universitario San Cecilio, Granada. ² Hospital Virgen de las Nieves, Granada. ³ Complejo Hospitalario de Jaén, Jaén (Spain).


OBJETIVES

The aim of the study is to evaluate the effectiveness and safety of tralokinumab in patients with moderate-severe AD in three tertiary hospitals.

MATERIALS AND METHODS



RESULTADOS



CONCLUSIONS

Tralokinumab is an innovative alternative in patients with moderate-severe AD refractory to other therapies. More data on long-term efficacy and safety are needed.

